Pharmacyte Biotech Inc (OTCMKTS:PMCB) biotech entity in clinical stage working to advance targeted treatments for patients suffering from diabetes and cancer utilizing Cell-in-a-Box® technology stated that Dr. Gerald W. Crabtree, Ph.D., the COO has been featured in an article of the ‘PharmaVOICE Magazine’, September edition.
Dr. Crabtree expressed that they involved leading experts for the advancement of their clinical development plans. Their guidance will prove extremely beneficial in moving forward with the treatment developments plans. This opportunity to be interviewed by the reputed magazine and to discuss the developments plans enables Pharmacyte to disclose the many benefits of having an excellent team to progress disease treatments.
Growblox Sciences Inc (OTCMKTS:GBLX) Appoints John Poss As New CFO
Growblox Sciences Inc (OTCMKTS:GBLX) a BioPharma company with advanced technologies in plant biology designed to grow medicinal cannabis, reported the appointment of Mr. John Poss as the new Chief Financial Officer of the company. Craig Ellins, the CEO said that first joining company as a consultant, the impressive performance of Poss and his contributions, made the recruiting of him as a full-time major executive an apparent choice.
The decision supports Growblox evolution from the engineering intensive development phase to the daily operations of growing an excellent product, branding it and enhancing revenue. Growblox management feels that Poss will be instrumental in assisting the company to sail through transition expeditiously and smoothly. On his new role, Mr. Poss said that he is delighted to join company. As a cancer survivor, he is a strong believer in the medicinal value of marijuana in several cases and to cure many diseases.
Sangamo Biosciences, Inc. (NASDAQ:SGMO) To Accelerate Advancement Of ZFP Therapeutics®
Sangamo Biosciences, Inc. (NASDAQ:SGMO) reported that the company have agreed to revise collaboration and license deal with Shire PLC (ADR) (NASDAQ:SHPG) to expedite the advancement of ZFP Therapeutics targeting Huntington’s and Hemophilia A and B disease.
DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of USmarketsDaily.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: